Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Purchases $2,454,344.00 in Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd bought 322,940 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were bought at an average cost of $7.60 per share, with a total value of $2,454,344.00. Following the transaction, the insider directly owned 5,200,767 shares of the company’s stock, valued at approximately $39,525,829.20. This trade represents a 6.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Wednesday, September 30th, L1 Capital Pty Ltd purchased 74,286 shares of Anteris Technologies Global stock. The shares were bought at an average price of $7.72 per share, for a total transaction of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total transaction of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total value of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.04, for a total transaction of $1,250,260.20.

Anteris Technologies Global Trading Down 2.1%

NASDAQ:AVR traded down $0.16 during trading hours on Thursday, hitting $7.61. 1,170,680 shares of the company traded hands, compared to its average volume of 718,688. The stock has a market capitalization of $741.67 million, a price-to-earnings ratio of -3.90 and a beta of 1.87. Anteris Technologies Global Corp. has a twelve month low of $3.30 and a twelve month high of $11.06. The firm has a 50-day moving average of $8.51 and a 200 day moving average of $7.98.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period last year, the company earned ($0.58) earnings per share. Equities research analysts predict that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of Anteris Technologies Global in a research note on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Anteris Technologies Global during the 2nd quarter valued at $56,846,000. Nantahala Capital Management LLC bought a new position in shares of Anteris Technologies Global in the second quarter valued at about $33,325,850. ADAR1 Capital Management LLC acquired a new position in Anteris Technologies Global during the 2nd quarter worth about $30,979,000. Perceptive Advisors LLC grew its holdings in Anteris Technologies Global by 104.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after acquiring an additional 1,750,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Anteris Technologies Global in the 2nd quarter valued at about $6,350,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.